344 Phase 3 trial of pembrolizumab and enzalutamide versus enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) (KEYNOTE-641)

by Arnulf Stenzl, Julie Nicole Graff, Joseph Burgents, Li Wen Liang
Published 2020-11-01